1.Executive Summary
A Special Cycle Hid the Structural One
Research window
2026-05-01 to 2026-05-31
Data vintage
Retrospective edition, researched through 2026-08-05
Linked sources
31 primary and attributable references
Mood 1.6 / 10 · Deeply bearish — false dawn
-0.1 vs. AprilMay offered enough positive numbers to support a recovery story and enough causal evidence to reject it. Chemical production rose from the prior quarter. Sales improved sequentially. Several companies protected earnings through cost savings, price, mix, or orders brought forward. Yet year-on-year output and sales remained sharply negative, business expectations collapsed, and Wacker formalized the removal of about 1,600 jobs in Germany.
This is the difference between a special cycle and a structural cycle. The special cycle was driven by precautionary inventories and disrupted imports after the Iran escalation. The structural cycle was driven by utilization, location costs, and investment. May improved the first and worsened the second.
Monitoring note. Events are assigned to May. The VCI first-quarter report published on May 29 is the month's central hard-data release. The Mood Index weights demand and output 40%, energy and inputs 20%, company decisions 20%, regulation 10%, and capital-market narrative 10%.
Source scope includes VCI, Destatis, and the Federal Ministry for Economic Affairs and Energy (BMWE, formerly BMWK). No ministry production series superseded the VCI/Destatis sector data in this window.
Mood Index: 1.6 / 10 — Deeply bearish, false dawn
Change from April: -0.1
| Indicator | Latest reading | Interpretation |
|---|---|---|
| Q1 chemical production | +2.0% q/q; -4.3% y/y | Sequential bounce from a depressed base |
| Q1 chem-pharma production | -2.8% q/q; -6.0% y/y | Pharma base effects pulled total lower |
| Q1 sector sales | €50.9bn; +2.1% q/q; -5.4% y/y | No revenue trend reversal |
| Chemical capacity utilization | 75.1% | Better, still below profitable operation |
| Sector employment | 471,500; about -1% | Job erosion continued |
| ifo May expectations | -42.0 | Forward view collapsed |
Top three events
- VCI declared that the first-quarter bounce was no trend reversal. Orders remained more than 20% below 2021, and employment fell to 471,500.
- Wacker agreed a framework to remove about 1,600 German jobs by the end of 2027. No forced redundancies did not make the Standort decision less material.
- Germany's industrial electricity guideline took effect, and the EU approved €5 billion for industrial decarbonization. Policy delivery accelerated just as investment appetite weakened.
Strategic conclusion
May's core finding is uncomfortable: public support became more concrete while private location confidence deteriorated. Subsidies can make an eligible project less expensive. They cannot compensate for an operating system in which permits, utilities, labor, carbon, and low utilization all move against the same site.
2.Macroeconomic & Regulatory Landscape
Demand, energy, policy, and the Standort D cost stack
Production, sales, and employment
The VCI's first-quarter report ended the data vacuum. Chemical output rose 2.0% from Q4 2025 but remained 4.3% below the prior year. Pharmaceuticals fell 10.1% quarter on quarter, largely because 2025 tariff-related pull-forwards distorted the comparison. Combined chemical and pharmaceutical production fell 2.8% quarter on quarter and 6.0% year on year.
Sales rose 2.1% sequentially to €50.9 billion but were 5.4% below Q1 2025. Domestic sales improved 4.0% from Q4, while foreign sales increased 1.0%; both remained below prior-year levels. Capacity utilization rose to 75.1%, still below the VCI's profitability threshold. Employment fell about 1% to 471,500. The chemical job decline outweighed modest pharmaceutical hiring.
The ifo survey added a sharper forward warning. The business climate fell to -30.2. Current conditions improved to -17.5, consistent with precautionary orders. Expectations collapsed to -42.0. One-third of companies reported material shortages, up from 7% in the first quarter, while the price-expectations balance jumped to +47.5.
Sources: VCI Q1 2026 report, VCI economic reports index, ifo May chemical climate, Reuters — VCI sees no recovery
Energy and chemical feedstocks
Producer energy prices fell 0.4% from April but remained 2.5% above the prior year. The aggregate concealed the chemical shock. Mineral-oil products were 34.9% more expensive year on year, naphtha 60.9%, and chemical feedstocks 10.4%, including a 5.8% monthly increase. Gas and electricity prices remained below prior-year levels.
The combination matters. A gas-intensive plant may have seen relief while a naphtha-based chain suffered acute inflation. “Energy costs” were no longer a sufficient unit of analysis. Product route, feedstock, contract timing, and pass-through determined the margin.
The federal industrial electricity guideline became effective on May 7. Eligible users could now plan around the scheme's 2026–2028 framework, although administrative conditions and reinvestment obligations remained. Strompreiskompensation continued as a distinct instrument for indirect carbon costs; it should not be conflated with the industrial electricity subsidy.
Sources: Destatis producer prices, May, Federal industrial electricity explainer
Green Deal, REACH, and subsidies
On May 6, the European Commission approved a €5 billion German state-aid scheme for industrial decarbonization. The scheme can help bridge the cost difference for lower-emission processes. Its effectiveness will depend on whether firms believe the underlying German asset will remain competitive long enough to earn a return after the aid period.
On May 11, the Commission published an implementing decision concerning a French provisional measure for creosote-treated wood. The decision was narrow, but it illustrated the persistent interaction between national restrictions and EU chemicals law. Revised CLP obligations due from July remained the larger operational deadline.
Sources: European Commission — €5 billion German decarbonization scheme, European Commission chemicals legislation, European Commission revised CLP rules
3.Corporate Movers & Shakers
Eight-company decision ledger and Standort D implications
| Company | May event | Standort D reading |
|---|---|---|
| BASF | No new May earnings release after April Q1; Ludwigshafen savings continued | Cost reduction remained the German-site mechanism |
| Bayer | Q1 sales €13.4bn; core EPS €2.71; free cash flow -€2.3bn, including litigation payments | Operations improved; litigation constrained capital allocation |
| Covestro | AGM approved transfer of minority shares to XRG at €59.46; XRG held 96.16% | Public-market exit nearly complete; ownership shifted to Abu Dhabi |
| Evonik | Q1 adjusted EBITDA €475m; sales €3.43bn, down 9%; 2026 outlook confirmed | Cost discipline offset weak volume and currency, not a demand turn |
| Lanxess | Q1 segments reported weak demand; full-year EBITDA range €450–550m confirmed | March job program remained necessary |
| Wacker Chemie | Framework agreed for about 1,600 German job reductions by end-2027 | Month's clearest negative Standort D decision |
| Henkel | Q1 organic sales +1.7%; five acquisitions represented about €1.6bn of sales; three closed | Portfolio growth contrasted with weak European organic sales |
| Merck KGaA | Q1 Life Science organic growth +8.3%; Electronics +4.2%; €20m metrology investment announced | AI-chip demand supported selective technology investment |
Wacker's agreement deserves precision. The reduction will be implemented without forced layoffs, using socially responsible measures. Yet the economic content is a reduction of roughly 15% of its German workforce from the 2025 base. The program targets more than €300 million in annual savings. High energy costs, weak demand, Chinese competition, and bureaucracy were not rhetorical complaints; they were inputs into a headcount decision.
Merck supplied the counterexample. Growth in Life Science and Electronics, including semiconductor materials linked to AI demand, supported investment in high-value metrology and inspection. Standort D remained investable where intellectual property, customer qualification, and process precision mattered more than bulk utility costs.
Sources: Bayer Q1 address, Covestro squeeze-out approval, Evonik Q1, Lanxess Q1, Wacker PACE agreement, Henkel Q1, Merck Q1
4.Innovation & Transformation
From pilots and platforms to bankable industrial scale
May's innovation story was shaped by state-aid economics. The €5 billion decarbonization scheme created a financing path for electrification, hydrogen, CCUS, and process conversion. It did not select projects for companies; it changed their relative hurdle rates.
Merck's metrology and inspection expansion provided a more immediate example. Semiconductor customers buying tools for AI-related capacity value precision, qualification, and proximity to expertise. Those characteristics protect margins from commodity import pressure. The lesson for German chemicals is not that every plant should become a chip-materials business. It is that Standort D works best where knowledge and integration outweigh utility disadvantages.
The circular-economy agenda continued toward the EU Circular Economy Act expected in 2026. The practical question remained feedstock quality and offtake, not ambition.
Sources: Merck events and highlights, European Commission circular economy
5.Financial, Narrative & Falsification Radar
Equities, analyst evidence, media language, and what would change the view
One-month equity performance
Method: April month-end to May month-end Xetra closes, unadjusted and rounded. Up is above +2%; Down below -2%; otherwise Neutral.
| Company | May performance | Trend |
|---|---|---|
| BASF | -7.2% | Down |
| Bayer | -4.0% | Down |
| Covestro | Takeover-capped near €59.46 | Neutral |
| Evonik | -4.9% | Down |
| Lanxess | -9.1% | Down |
| Wacker Chemie | +6.0% | Up |
| Henkel | +7.4% | Up |
| Merck KGaA | +18.9% | Up |
The split followed business quality and event exposure. Merck, Henkel, and Wacker benefited from earnings or portfolio evidence. BASF, Evonik, and Lanxess tracked the worsening chemical macro. Bayer remained litigation-discounted despite better operating sales.
Analyst-rating tape
No attributable Deutsche Bank or Goldman Sachs upgrade or downgrade for the eight companies was verified in May. The month's share-price dispersion was therefore driven more clearly by company results and macro repricing than by a documented major-bank recommendation reversal.
Price sources: BASF, Bayer, Covestro, Evonik, Lanxess, Wacker, Henkel, Merck KGaA. Rating source: Deutsche Bank recommendation history.
Headline and Mood Index
Media method: Public headlines and indexed snippets from Handelsblatt, FAZ, CHEManager, and Börsen-Zeitung were reviewed for vocabulary and emphasis. Paywalled or crawler-restricted text was not used as the sole support for a factual claim.
May's headlines were divided between “earnings resilience” and “no trend reversal.” The second framing was analytically stronger because it explained the first. Cost savings and precautionary orders can lift EBITDA during a weak cycle. They do not create sustainable end demand.
| Keyword | May signal | Reading |
|---|---|---|
| Deindustrialization | Very high | 1,600 German Wacker jobs and weak private investment |
| Recovery | Low | Sequential output and selected company beats |
| Crisis | Very high | Expectations at -42.0 and feedstock inflation |
Sources: Handelsblatt — April climate at three-year low, Reuters — no VCI recovery, CHEManager home and industry coverage
What Would Change the View?
May's pessimism would be too severe if precautionary orders became genuine final demand and if the electricity and decarbonization schemes triggered domestic project commitments. The observable test is not applications for aid. It is board-approved capital expenditure. Until that changes, the special cycle is camouflage.